Another win for CogState
Tuesday, 12 August, 2008
CogState [ASX: CGS] has signed a contract worth $1.2 million which will see the company provide technology to a major pharmaceutical company for use in a Phase III schizophrenia study.
The cognition specialist company will be providing its computerised cognitive testing technology for the trial, which is to be conducted in over 70 sites.
This is the ninth contract the company has signed since July.
The nine contracts have a combined value of $2.3 million, and CogState is expecting that 63 per cent of the contracts' revenue will be earned in the coming financial year.
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
